The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES)
Abstract
Background —In congestive heart failure (CHF), extracellular matrix turnover is a major determinant of cardiac remodeling. It has been suggested that spironolactone may decrease cardiac fibrosis. We investigated the interactions between serum markers of cardiac fibrosis and the effect of spironolactone on outcome in patients with CHF. Methods and Results —A sample of 261 patients from the Randomized Aldactone Evaluation Study (RALES) were randomized to placebo or spironolactone (12.5 to 50 mg daily). Serum procollagen type I carboxy-terminal peptide, procollagen type I amino-terminal peptide, and procollagen type III amino-terminal peptide (PIIINP) were assessed at baseline and at 6 months. Baseline PIIINP >3.85 μg/L was associated with an increased risk of death (relative risk [RR] 2.36, 95% CI 1.34 to 4.18) and of death+hospitalization (RR 1.83, 95% CI 1.18 to 2.83). At 6 months, markers decreased in the spironolactone group but remained unchanged in the placebo group. The spironolactone effect on outcome was significant only in patients with above-median baseline levels of markers. RR (95% CI) values for death among patients receiving spironolactone were 0.44 (0.26 to 0.75) and 1.11 (0.66 to 1.88) in subgroups of PIIINP levels above and below the median, respectively. Similarly, RR (95% CI) values for death+hospitalization among patients receiving spironolactone were 0.45 (0.29 to 0.71) and 0.85 (0.55 to 1.33), respectively. Conclusions —In patients with CHF, high baseline serum levels of markers of cardiac fibrosis synthesis are significantly associated with poor outcome and decrease during spironolactone therapy. The benefit from spironolactone was associated with higher levels of collagen synthesis markers. These results suggest that limitation of the excessive extracellular matrix turnover may be one of the various extrarenal mechanisms contributing to the beneficial effect of spironolactone in patients with CHF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationMatrix metalloproteinases and their inhibitors in connective tissue remodeling
Woessner, J. F. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.8.1850705 · Cited by 3,282
Molecular Mechanisms of Myocardial Remodeling
SWYNGHEDAUW, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.215 · Cited by 1,460
Collagen remodeling after myocardial infarction in the rat heart.
Cleutjens, J. P. M., Verluyten, M. J., Smiths, J. F., & Daemen, M. J. A. P. (1995) · Europe PMC (PubMed Central) · Cited by 550
Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen
Melkko, J., Niemi, S., Risteli, L., & Risteli, J. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.7.1328 · Cited by 513
Infarct scar: a dynamic tissue
Sun, Y. (2000) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00032-8 · Cited by 510
Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.
Brilla, C. G., & Weber, K. T. (1992) · PubMed · Cited by 505
Mineralocorticoids, hypertension, and cardiac fibrosis.
Young, M., Fullerton, M., Dilley, R., & Funder, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117269 · Cited by 437
Brilla, C. G., Matsubara, L. S., & Weber, K. T. (1993) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1993.1066 · Cited by 425
The alpha-smooth muscle actin-positive cells in healing human myocardial scars.
WILLEMS, I. E. M. G., Havenith, M. G., Mey, J. G. R. D., & Daemen, M. J. A. P. (1994) · PubMed Central · Cited by 385
Querejeta, R., Varo, N., López, B., Larman, M., Artiñano, E., Etayo, J. C., Ubago, J. L. M., Gutierrez-Stampa, M., Emparanza, J. I., Gil, M. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.14.1729 · Cited by 368
MacFadyen, R. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00091-6 · Cited by 339
Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen.
Risteli, J., Niemi, S., Trivedi, P., Mäentausta, O., Mowat, A. P., & Risteli, L. (1988) · Clinical Chemistry · doi:10.1093/clinchem/34.4.715 · Cited by 336
Abnormalities of the Extracellular Degradation of Collagen Type I in Essential Hypertension
Laviades, C., Varo, N., Fernández, J., Mayor, G., Gil, M. J., Monreal, I., & Díez, J. (1998) · Circulation · doi:10.1161/01.cir.98.6.535 · Cited by 298
Zannad, F., Briancon, S., Juilliere, Y., Mertes, P.-M., Villemot, J.-P., Alla, F., & Virion, J.-M. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00634-2 · Cited by 295
Self-citationImmunoassay for intact amino-terminal propeptide of human type I procollagen
Melkko, J., Kauppila, S., Niemi, S., Risteli, L., Haukipuro, K., Jukkola, A., & Risteli, J. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.6.947 · Cited by 283
Denhardt, D. T., Feng, B., Edwards, D. R., Cocuzzi, E. T., & Malyankar, U. M. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90074-n · Cited by 269
Klappacher, G., Franzen, P., Haab, D., Mehrabi, M., Binder, M., Plesch, K., Pacher, R., Grimm, M., Pribill, I., Eichler, H.-G., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80686-9 · Cited by 258
Díez, J., Laviades, C., Mayor, G., Gil, M. J., & Monreal, I. (1995) · Circulation · doi:10.1161/01.cir.91.5.1450 · Cited by 217
Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension.
Robert, V, Van Thiem, N., Cheav, S. L., Mouas, C., Swynghedauw, B., & Delcayre, C. (1994) · Hypertension · doi:10.1161/01.hyp.24.1.30 · Cited by 180
Analysis of healing after myocardial infarction using polarized light microscopy.
Whittaker, P., Boughner, D. R., & Kloner, R. A. (1989) · Europe PMC (PubMed Central) · Cited by 174
CAMPBELL, S., Janicki, J., & Weber, K. T. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(95)90359-3 · Cited by 148
Aldosterone and Spironolactone in Heart Failure
Weber, K. T. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411009 · Cited by 128
Collagen Scar Formation After Acute Myocardial Infarction
Uusimaa, P., Risteli, J., Niemelä, M. J., Lumme, J., Ikäheimo, M. J., Jounela, A. J., & PEUHKURINEN, K. J. (1997) · Circulation · doi:10.1161/01.cir.96.8.2565 · Cited by 124
Serum Markers of Collagen Type I Metabolism in Spontaneously Hypertensive Rats
Dı́ez, J., Panizo, Á., Gil, M. J., Monreal, I., Hernández, M., & Pardo‐Mindán, J. (1996) · Circulation · doi:10.1161/01.cir.93.5.1026 · Cited by 120
Risteli, J., & Risteli, L. (1995) · PubMed · Cited by 120
Aldosterone and cardiac fibrosis: in vitro studies
Fullerton, M., & Funder, J. W. (1994) · Cardiovascular Research · doi:10.1093/cvr/28.12.1863 · Cited by 115
Monitoring tissue repair and fibrosis from a distance.
Kt, W. (1997) · PubMed · Cited by 91
Brilla, C. G., Maisch, B., & Weber, K. T. (1993) · Journal of Molecular Medicine · doi:10.1007/bf00180074 · Cited by 82
Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction.
Jensen, L. T., Hørslev-Petersen, K., Toft, P. B., Bentsen, K. D., Grande, P., Simonsen, E. E., & Lorenzen, I. (1990) · Circulation · doi:10.1161/01.cir.81.1.52 · Cited by 82
Thrombolytic therapy with streptokinase stimulates collagen breakdown.
PEUHKURINEN, K. J., Risteli, L., Melkko, J., et al. (1991) · Circulation · doi:10.1161/01.cir.83.6.1969 · Cited by 80
Sato, Y., Kataoka, K., Matsumori, A., Sasayama, S., Yamada, T., Ito, H., & Takatsu, Y. (1997) · Heart · doi:10.1136/hrt.78.5.505 · Cited by 78
Høst, N. B., Jensen, L. T., Bendixen, P. M., Jensen, S. E., Koldkjær, O. G., & Simonsen, E. E. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80251-3 · Cited by 77
Zannad, F. M. (1995) · European Heart Journal · doi:10.1093/eurheartj/16.suppl_n.98 · Cited by 69
Self-citationAnalytical Aspects Regarding the Measurement of Metalloproteinases and Their Inhibitors in Blood
Lein, M., Nowak, L., Jung, K., Koenig, F., Lichtinghagen, R., Schnorr, D., & Loening, S. A. (1997) · Clinical Biochemistry · doi:10.1016/s0009-9120(97)00097-0 · Cited by 61
Monitoring fibrillar collagen turnover in hypertensive heart disease
Dı́ez, J. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00072-2 · Cited by 59
Angiotensin-converting enzyme inhibitor and spironolactone combination therapy
Zannad, F. M. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90243-6 · Cited by 39
Self-citation
Cited by
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
Braunwald, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800239 · Cited by 1,257
Spinale, F. G. (2007) · Physiological Reviews · doi:10.1152/physrev.00012.2007 · Cited by 1,120
Flett, A. S., Hayward, M. P., Ashworth, M. T., Hansen, M. S., Taylor, A. M., Elliott, P. M., McGregor, C., & Moon, J. C. (2010) · Circulation · doi:10.1161/circulationaha.109.930636 · Cited by 915
Metadata
- Authors
- Zannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B.
- Venue
- Circulation
- Published
- 2000-11-28
- Volume
- 102
- Issue
- 22
- Pages
- 2700-2706
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2106493153
- Cited by
- 947
- References
- 37
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.